Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.90 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.90 |
| ▸ | MAPT | P10636 | 3/20 | 0.90 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.90 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.90 |
| ▸ | MEN1 | O00255 | 2/20 | 0.90 |
| ▸ | HPGD | P15428 | 2/20 | 0.90 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.90 |
| ▸ | ABCG2 | Q9UNQ0 | 5/20 | 0.78 |
| ▸ | TP53 | P04637 | 2/20 | 0.72 |
| ▸ | USP2 | O75604 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.72 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.72 |
| ▸ | CXCL12 | P48061 | 2/20 | 0.71 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.71 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.71 |
| ▸ | RELA | Q04206 | 2/20 | 0.71 |
| ▸ | DPP4 | P27487 | 1/20 | 0.71 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30384102 | 1.00 | TDP1 (0.90) | TDP1CYP3A4MAPTKMT2AKDM4E | |
| SCHEMBL5088525 | 1.00 | TDP1 (0.90) | TDP1CYP3A4MAPTKMT2AKDM4E | |
| SCHEMBL5084292 | 0.95 | CYP3A4 (1.00) | TDP1CYP3A4MAPTKMT2AKDM4E | |
| SCHEMBL5084287 | 0.95 | CYP3A4 (1.00) | TDP1CYP3A4MAPTKMT2AKDM4E | |
| SCHEMBL30383925 | 0.95 | CYP3A4 (1.00) | TDP1CYP3A4MAPTKMT2AKDM4E | |
| SCHEMBL25196891 | 0.92 | ABCG2 (0.78) | TDP1CYP3A4MAPTKMT2AKDM4E | |
| SCHEMBL31233076 | 0.92 | ABCG2 (0.78) | TDP1CYP3A4MAPTKMT2AKDM4E | |
| SCHEMBL25265249 | 0.92 | MAPT (0.90) | TDP1CYP3A4MAPTKMT2AKDM4E | |
| SCHEMBL25195888 | 0.92 | MAPT (0.90) | TDP1CYP3A4MAPTKMT2AKDM4E | |
| SCHEMBL30383344 | 0.89 | KMT2A (0.90) | TDP1CYP3A4MAPTKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2017132135-A1 | ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-08-03 | — | — | WO | disclosed |
| WO-2007115181-A9 | COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF | EASTMAN CHEM CO (US) | 2008-04-03 | — | — | WO | disclosed |
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | EASTMAN CHEMICAL COMPANY | 2007-11-01 | — | — | US | disclosed |
| WO-2007115181-A2 | COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF | EASTMAN CHEMICAL COMPANY (US) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | ABCC4, NCOA4, NR4A3 | TDP1 4729/4885CYP3A4 17/4885MAPT 4566/4885 |
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | TDP1 3071/4885CYP3A4 928/4885MAPT 3297/4885 |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | SERPINC1, SERPINE1, SERPINH1 | TDP1 3151/4885CYP3A4 1589/4885MAPT 3512/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | TDP1 3151/4885CYP3A4 1589/4885MAPT 3512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.